Title: Dendritic cell therapy in advanced gastric cancer: A promising new hope?
| dc.contributor.author | Mallika Tewari | |
| dc.contributor.author | Shipra Sahai | |
| dc.contributor.author | Raghvendra R. Mishra | |
| dc.contributor.author | Sunit K. Shukla | |
| dc.contributor.author | Hari S. Shukla | |
| dc.date.accessioned | 2026-02-07T05:33:12Z | |
| dc.date.issued | 2012 | |
| dc.description.abstract | Advanced gastric cancer carries a very poor prognosis when the tumor becomes unresectable. Even with the best currently available chemotherapy regimens the survival rate remains dismal. A recent breakthrough in the treatment paradigm has been the approval of trastuzumab, a monoclonal antibody, in HER2-positive metastatic gastric cancer. A large number of trials are underway using dendritic cells (DCs) in a number of human malignancies and do show a ray of hope in management of these patients. This review attempts to summarize tumor immunology and the current data regarding use of DCs in gastric cancer therapy. © 2012 Elsevier Ltd. All rights reserved. | |
| dc.identifier.doi | 10.1016/j.suronc.2012.03.003 | |
| dc.identifier.issn | 18793320 | |
| dc.identifier.uri | https://doi.org/10.1016/j.suronc.2012.03.003 | |
| dc.identifier.uri | https://dl.bhu.ac.in/bhuir/handle/123456789/23675 | |
| dc.subject | Cancer vaccine | |
| dc.subject | Dendritic cell | |
| dc.subject | Gastric cancer | |
| dc.subject | Immune escape | |
| dc.title | Dendritic cell therapy in advanced gastric cancer: A promising new hope? | |
| dc.type | Publication | |
| dspace.entity.type | Review |